Sanctuary Advisors LLC Makes New Investment in enVVeno Medical Corporation (NASDAQ:NVNO)

Sanctuary Advisors LLC purchased a new position in shares of enVVeno Medical Corporation (NASDAQ:NVNO) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 12,000 shares of the company’s stock, valued at approximately $39,000. Sanctuary Advisors LLC owned approximately 0.07% of enVVeno Medical at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Westside Investment Management Inc. raised its position in shares of enVVeno Medical by 132.0% during the 4th quarter. Westside Investment Management Inc. now owns 205,025 shares of the company’s stock worth $619,000 after buying an additional 116,650 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of enVVeno Medical by 7.8% in the 3rd quarter. Geode Capital Management LLC now owns 150,676 shares of the company’s stock worth $506,000 after purchasing an additional 10,902 shares during the last quarter. Fermata Advisors LLC grew its stake in shares of enVVeno Medical by 18.1% in the 4th quarter. Fermata Advisors LLC now owns 35,706 shares of the company’s stock worth $108,000 after purchasing an additional 5,481 shares during the last quarter. Hohimer Wealth Management LLC acquired a new position in shares of enVVeno Medical in the 3rd quarter worth approximately $286,000. Finally, Maven Securities LTD acquired a new position in shares of enVVeno Medical in the 3rd quarter worth approximately $295,000. 34.71% of the stock is currently owned by institutional investors.

enVVeno Medical Price Performance

Shares of NVNO opened at $3.00 on Friday. The firm’s 50 day moving average is $3.30 and its 200-day moving average is $3.64. The stock has a market capitalization of $52.61 million, a P/E ratio of -2.33 and a beta of 1.38. enVVeno Medical Corporation has a 12-month low of $2.45 and a 12-month high of $6.50.

enVVeno Medical (NASDAQ:NVNO) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.05. As a group, equities research analysts forecast that enVVeno Medical Corporation will post -1.32 EPS for the current fiscal year.

enVVeno Medical Profile

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).